GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (OTCPK:ACORQ) » Definitions » Interest Coverage

Acorda Therapeutics (Acorda Therapeutics) Interest Coverage : 0.16 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Acorda Therapeutics's Operating Income for the three months ended in Dec. 2023 was $1.5 Mil. Acorda Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $-9.2 Mil. Acorda Therapeutics's interest coverage for the quarter that ended in Dec. 2023 was 0.16. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Acorda Therapeutics's Interest Coverage or its related term are showing as below:


ACORQ's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.1
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Acorda Therapeutics Interest Coverage Historical Data

The historical data trend for Acorda Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Acorda Therapeutics Interest Coverage Chart

Acorda Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Acorda Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 - - - 0.16

Competitive Comparison of Acorda Therapeutics's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acorda Therapeutics's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's Interest Coverage falls into.



Acorda Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Acorda Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Acorda Therapeutics's Interest Expense was $-31.5 Mil. Its Operating Income was $-23.3 Mil. And its Long-Term Debt & Capital Lease Obligation was $3.2 Mil.

Acorda Therapeutics did not have earnings to cover the interest expense.

Acorda Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Acorda Therapeutics's Interest Expense was $-9.2 Mil. Its Operating Income was $1.5 Mil. And its Long-Term Debt & Capital Lease Obligation was $3.2 Mil.

Interest Coverage=-1* Operating Income (Q: Dec. 2023 )/Interest Expense (Q: Dec. 2023 )
=-1*1.481/-9.2
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Acorda Therapeutics  (OTCPK:ACORQ) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Acorda Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Acorda Therapeutics (Acorda Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Executives
Thomas M. Burns director 2910 SEVENTH STREET, BERKELEY CA 94710
Ron Cohen officer: CEO and President C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
John Varian director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Michael A Gesser officer: Chief Financial Officer 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Neil S. Belloff officer: General Counsel 11 RADNOR LANE, MAHOPAC NY 10541
Kerry M Clem officer: Chief Commercial Officer 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Morales officer: Interim PAO & PFO 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Jane Wasman officer: Exec V Pres, Gen Cnsl & Sec C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella officer: Exec. VP-Commercial Dvlpmnt C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
David Lawrence officer: Chief Financial Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Capital Management Lp 10 percent owner 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Lorin Randall director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Burkhard Blank officer: Chief Medical Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Scopia Management, Inc. 10 percent owner 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019
Matthew Sirovich 10 percent owner C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123

Acorda Therapeutics (Acorda Therapeutics) Headlines